This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: March 2nd, 2011 - March 2nd, 2012
The educational design of this activity addresses the needs of physicians, nurses, and pharmacists involved in the treatment of patients with multiple myeloma (MM).
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with MM.
After completing this activity, the participant should be better able to:
- Describe optimal frontline treatment options for patients with newly diagnosed MM
- Describe current opinion on maintenance therapy for MM
- List therapeutic options for patients with relapsed/refractory MM
- Summarize key clinical data on the use of novel agents in the treatment of MM as presented at the American Society of Hematology (ASH) 2010 annual meeting
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Edu cation (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hours.
Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.5 contact hours (0.15 CEUs) of continuing education credit. The universal activity number for this activity is 0468-9999-11-002-H01-P.
There is no fee for this activity. To receive credit after reading this CME/CE activity in its entirety, participants must complete the posttest and evaluation. The posttest and evaluation can be completed online at www.mlicme.org/P10006.html. Upon completion of the evaluation and scoring a 70% or better on the posttest, you will immediately receive your certificate online. If you do not achieve a score of 70% or better on the posttest, you will be asked to take it again. Please retain a copy of the Certificate for your records.
Disclosure of Conflicts of Interest
Before the activity, all faculty and anyone that is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Kenneth C. Anderson, MD is a consultant and is on advisory boards for BMS, Celgene, Millennium, Novartis, and Onyx.
William Bensinger, MD has received research support from and is a consultant for Celgene, Millennium, and Onyx. He is also on the speakers bureau for Celgene.
Paul Richardson, MD is on advisory boards for BMS, Celgene, Johnson & Johnson, Millennium, and Novartis.
Jesús F. San Miguel, MD has received honoraria from Celgene, Janssen, and Millennium.
Evangelos Terpos, MD, PhD is on advisory boards for Amgen and Novartis. He also serves on a steering committee for Amgen and has received honoraria from Amgen, Janssen-Cilag, and Novartis.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Karen Cooksey, Amanda Glazar, PhD, Jackie Dawson, MSN, Kathryn Gada, MSN, and Nancy Nesser, JD, PharmD have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Medical Learning Institute do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
Agenda: 1.5 hours
Articles/Commentaries: 75 minutes
Evaluation/Posttest: 15 minutes